Meridian Bioscience Inc (NASDAQ:VIVO) Sentiment Worsened, Because

May 17, 2018 - By Hannah Black

Meridian Bioscience, Inc. (NASDAQ:VIVO) Logo

Sentiment for Meridian Bioscience Inc (NASDAQ:VIVO)

Meridian Bioscience Inc (NASDAQ:VIVO) institutional sentiment decreased to 1.2 in 2017 Q4. Its down -0.17, from 1.37 in 2017Q3. The ratio has dropped, as 78 hedge funds increased and started new holdings, while 65 decreased and sold their stock positions in Meridian Bioscience Inc. The hedge funds in our partner’s database now have: 36.52 million shares, up from 36.26 million shares in 2017Q3. Also, the number of hedge funds holding Meridian Bioscience Inc in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 21 Reduced: 44 Increased: 47 New Position: 31.

Meridian Bioscience, Inc., a life science company, develops, makes, distributes, and sells diagnostic test kits primarily for various gastrointestinal, viral, respiratory, and parasitic infectious diseases worldwide. The company has market cap of $593.88 million. The firm operates through Diagnostics and Life Science divisions. It has a 27.5 P/E ratio. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the illumigene brand; rapid immunoassays, a single-use immunoassays that can be used in point-of-care settings under the TRU, ImmunoCard, and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the Premier brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand.

The stock decreased 0.53% or $0.075 during the last trading session, reaching $14.025. About 252,265 shares traded. Meridian Bioscience, Inc. (NASDAQ:VIVO) has risen 7.87% since May 17, 2017 and is uptrending. It has underperformed by 3.68% the S&P500.

Analysts await Meridian Bioscience, Inc. (NASDAQ:VIVO) to report earnings on July, 26. They expect $0.17 EPS, up 6.25 % or $0.01 from last year’s $0.16 per share. VIVO’s profit will be $7.20M for 20.63 P/E if the $0.17 EPS becomes a reality. After $0.21 actual EPS reported by Meridian Bioscience, Inc. for the previous quarter, Wall Street now forecasts -19.05 % negative EPS growth.

Brown Capital Management Llc holds 0.79% of its portfolio in Meridian Bioscience, Inc. for 4.67 million shares. Clark Estates Inc Ny owns 227,000 shares or 0.52% of their US portfolio. Moreover, Lucus Advisors Llc has 0.47% invested in the company for 23,042 shares. The Pennsylvania-based Connors Investor Services Inc has invested 0.4% in the stock. Ronna Sue Cohen, a Utah-based fund reported 36,570 shares.

Since January 1, 0001, it had 2 insider purchases, and 0 selling transactions for $28,784 activity.

Meridian Bioscience, Inc. (NASDAQ:VIVO) Ratings Coverage

Ratings analysis reveals 0 of Meridian Bioscience Inc’s analysts are positive. Out of 3 Wall Street analysts rating Meridian Bioscience Inc, 0 give it “Buy”, 1 “Sell” rating, while 2 recommend “Hold”. The lowest target is $11.0 while the high is $16.0. The stock’s average target of $14.33 is 2.17% above today’s ($14.025) share price. VIVO was included in 3 notes of analysts from January 25, 2018. Piper Jaffray maintained it with “Sell” rating and $11.0 target in Thursday, January 25 report. The rating was maintained by Robert W. Baird on Thursday, January 25 with “Hold”. The company was maintained on Thursday, January 25 by Canaccord Genuity.

Meridian Bioscience, Inc. (NASDAQ:VIVO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: